Syndax Pharmaceuticals Inc
SNDXHealthcare|Biotechnology|USA
$23.62
-1.23 (-4.95%)
Tangible Book
$0.47
About
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Stock Price
+140.5%(1Y)
Pipeline Summary
51 total trials29
Phase 1
29
Phase 2
1
Phase 3
0
Phase 4
Terminated: 10Recruiting: 8Active: 5Completed: 24NO_LONGER_AVAILABLE: 1NOT_YET_RECRUITING: 1Withdrawn: 2
Active Trials (13)
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT05360160Acute Myeloid Leukemia
Phase 1Phase 2Recruiting
Enrollment: 43 participants
High Dose IL 2 and Entinostat in RCC
NCT03501381Renal Cell Carcinoma
Phase 2Active
Enrollment: 46 participants
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04710576Chronic Graft-versus-host-disease
Phase 2Recruiting
Enrollment: 296 participants
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571Acute Myeloid Leukemias
Phase 1Active
Enrollment: 76 participants
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256Idiopathic Pulmonary Fibrosis
Phase 2Active
Enrollment: 145 participants
BioScore
5.6/10
Watchlist
Ownership
Recent Insider Trades
Metzger Michael ASELL
2026-07-0832,375 shares @ $24.24
Botwood Nicholas A.J.SELL
2026-06-1265,515 shares @ $18.07
Metzger Michael ASELL
2026-06-016,847 shares @ $18.99
Goldan Keith A.SELL
2026-06-011,177 shares @ $18.99
Metzger Michael ASELL
2026-02-0917,159 shares @ $21.03
Data last updated: Jul 12, 2026, 07:38 PM